HRP20170444T1 - Projektirana anti-il-23 antitijela - Google Patents

Projektirana anti-il-23 antitijela Download PDF

Info

Publication number
HRP20170444T1
HRP20170444T1 HRP20170444TT HRP20170444T HRP20170444T1 HR P20170444 T1 HRP20170444 T1 HR P20170444T1 HR P20170444T T HRP20170444T T HR P20170444TT HR P20170444 T HRP20170444 T HR P20170444T HR P20170444 T1 HRP20170444 T1 HR P20170444T1
Authority
HR
Croatia
Prior art keywords
antibody
binding fragment
antigen
seq
residues
Prior art date
Application number
HRP20170444TT
Other languages
English (en)
Inventor
Leonard G. Presta
Peter Orth
Brian M. Beyer
Yan-Hui Liu
Richard N. Ingram
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37685722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20170444(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of HRP20170444T1 publication Critical patent/HRP20170444T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (17)

1. Antitijelo, ili njegov antigen-vežući fragment, naznačen time, što se veže za humani IL- 23p19 na epitopu koji sadrži rezidue 82-95 i rezidue 133-140 SEQ ID NO: 29.
2. Antitijelo, ili njegov antigen-vežući fragment, iz zahtjeva 1, naznačen time, što se veže za epitop koji sadrži rezidue E82, G86, S87, D88, T91, G92, E93, P94, S95, H106, P133, S134, Q135, P136, W137, R139 i L140 SEQ ID NO: 29.
3. Antitijelo, ili njegov antigen-vežući fragment, iz zahtjeva 1, naznačen time, što antitijelo sadrži: CDRL1 koji se sastoji od rezidua 43-53 SEQ ID NO: 4; CDRL2 koji se sastoji od rezidua 69-75 SEQ ID NO: 4; CDRL3 koji se sastoji od rezidua 108-116 SEQ ID NO: 4; CDRH1 koji se sastoji od rezidua 45-54 SEQ ID NO: 3; CDRH2 koji se sastoji od rezidua 69-85 SEQ ID NO: 3; i CDRH3 koji se sastoji od rezidua 118-123 SEQ ID NO: 3.
4. Antitijelo, ili njegov antigen-vežući fragment, iz zahtjeva 3, naznačen time, što: varijabilna regija lakog lanca antitijela, ili njegovog vežućeg fragmenta, sadrži sekvencu rezidua 20-129 SEQ ID NO: 4, ili njenu varijantu; i varijabilna regija teškog lanca antitijela, ili njegovog vežućeg fragmenta, sadrži sekvencu rezidua 20-134 SEQ ID NO: 3, ili njenu varijantu; pri čemu varijanta sadrži do 20 konzervativno modificiranih aminokiselinskih supstitucija.
5. Antitijelo, ili njegov antigen-vežući fragment, iz zahtjeva 4, naznačen time, što je vezujući spoj antitijelo, ili njegov vežući fragment, koji uključuje: varijabilnu regiju lakog lanca koji sadrži rezidue 20-129 SEQ ID NO: 4; i varijabilnu regiju teškog lanca koji sadrži rezidue 20-134 SEQ ID NO: 3.
6. Antitijelo ili njegov antigen-vežući fragment iz zahtjeva 3, naznačen time, što blokira aktivnost posredovanu IL-23.
7. Izolirana nukleinska kiselina, naznačena time, što kodira varijabilnu regiju lakog lanca i varijabilnu regiju teškog lanca antitijela, ili njegovog antigen-vežućeg fragmenta, iz zahtjeva 4.
8. Ekspresijski vektor, naznačen time, što sadrži nukleinsku kiselinu iz zahtjeva 7 operabilno povezanu sa kontrolnim sekvencama koje prepoznaje stanica-domaćin, kada se stanica-domaćin transfektira vektorom.
9. Stanica-domaćin, naznačena time, što sadrži ekspresijski vektor iz zahtjeva 8.
10. Metoda proizvodnje polipeptida, naznačena time, što uključuje: kultiviranje stanice-domaćina iz zahtjeva 9 u kultivacijskom mediju pod uvjetima pod kojima se eksprimira sekvenca nukleinske kiseline, čime se proizvode polipeptidi koji sadrže varijabilne regije lakog i teškog lanca; i sakupljanje polipeptida iz stanice-domaćina ili kultivacijskog medija.
11. Antitijelo, ili njegov antigen-vežući fragment, iz zahtjeva 2, naznačen time, što sadrži konstantnu regiju humanog γ1 teškog lanca.
12. Antitijelo ili njegov antigen-vežući fragment iz zahtjeva 2, naznačen time, što sadrži konstantnu regiju humanog γ4 teškog lanca.
13. Antitijelo, ili njegov antigen-vežući fragment, iz zahtjeva 1, naznačen time, što se fragment antitijela bira iz grupe koja se sastoji od Fab, Fab’, Fab’-SH, Fv, scFv, F(ab’)2 i dijatela.
14. Smjesa, naznačena time, što sadrži antitijelo, ili njegov antigen-vežući fragment, iz zahtjeva 4 u kombinaciji sa farmaceutski prihvatljivim nosačem ili razblaživačem.
15. Smjesa iz zahtjeva 14, naznačena time, što sadrži još i imunosupresivno ili antiupalnog sredstvo.
16. Stanica-domaćin, naznačena time, što sadrži: (a) ekspresijski vektor koji uključuje sekvencu nukleinske kiseline koja kodira laki lanac antitijela, ili njegovog antigen-vežućeg fragmenta, iz zahtjeva 4; i (b) ekspresijski vektor koji uključuje sekvencu nukleinske kiseline koja kodira teški lanac antitijela, ili njegovog antigen-vežućeg fragmenta, iz zahtjeva 4.
17. Metoda proizvodnje vežućeg spoja naznačena time, što uključuje: kultiviranje stanice-domaćina iz zahtjeva 16 u kultivacijskom mediju pod uvjetima u kojima se eksprimiraju sekvence nukleinske kiseline, čime se proizvode polipeptidi koji sadrže lake i teške lance antitijela, ili njegovog antigen-vežućeg fragmenta; i sakupljanje antitijela, ili njegovog antigen-vežućeg fragmenta iz stanice-domaćina ili kultivacijskog medija.
HRP20170444TT 2005-08-31 2017-03-20 Projektirana anti-il-23 antitijela HRP20170444T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71358505P 2005-08-31 2005-08-31
PCT/US2006/033764 WO2007027714A2 (en) 2005-08-31 2006-08-29 Engineered anti-il-23 antibodies
EP06802592.3A EP1931710B1 (en) 2005-08-31 2006-08-29 Engineered anti-il-23 antibodies

Publications (1)

Publication Number Publication Date
HRP20170444T1 true HRP20170444T1 (hr) 2017-05-19

Family

ID=37685722

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170444TT HRP20170444T1 (hr) 2005-08-31 2017-03-20 Projektirana anti-il-23 antitijela

Country Status (17)

Country Link
US (3) US7807160B2 (hr)
EP (3) EP2354160A1 (hr)
JP (2) JP5350793B2 (hr)
CN (1) CN101296944A (hr)
CA (1) CA2620802A1 (hr)
CY (2) CY1118760T1 (hr)
DK (1) DK1931710T3 (hr)
ES (1) ES2619845T3 (hr)
HR (1) HRP20170444T1 (hr)
HU (2) HUE032131T2 (hr)
LT (2) LT1931710T (hr)
ME (1) ME02705B (hr)
PL (1) PL1931710T3 (hr)
PT (1) PT1931710T (hr)
RS (1) RS55788B1 (hr)
SG (2) SG165322A1 (hr)
WO (1) WO2007027714A2 (hr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3501537A1 (en) 2005-06-30 2019-06-26 Janssen Biotech, Inc. Anti-il23 antibodies, compositions, methods and uses
EP2354160A1 (en) 2005-08-31 2011-08-10 Schering Corporation Engineered anti-IL-23-antibodies
US20080199460A1 (en) 2005-09-01 2008-08-21 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
AU2006342792A1 (en) * 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
PL1971366T3 (pl) 2005-12-29 2015-01-30 Janssen Biotech Inc Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie
US7790862B2 (en) * 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
US7910703B2 (en) * 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US8414897B1 (en) * 2006-10-02 2013-04-09 The Uab Research Foundation Pathway for Th-17 cell development and methods utilizing same
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
SG178804A1 (en) * 2007-02-23 2012-03-29 Schering Corp Engineered anti-il-23p19 antibodies
BRPI0807710B1 (pt) 2007-02-23 2021-12-14 Merck Sharp & Dohme Corp Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
EP2056838B1 (en) 2007-02-28 2013-09-25 Merck Sharp & Dohme Corp. Combination therapy for treatment of immune disorders
US8119133B2 (en) 2007-02-28 2012-02-21 Schering Corporation Engineered anti-IL-23R antibodies
US7981415B2 (en) * 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
US7771720B2 (en) * 2007-09-07 2010-08-10 Cisthera, Inc. Humanized PAI-1 antibodies
US20100203009A1 (en) * 2007-10-02 2010-08-12 The Uab Research Foundation Pathway for Th-17 Cell Development and Methods Utilizing Same
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
CA3069576A1 (en) 2008-01-09 2009-07-16 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
MX2011001409A (es) 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
JP5931442B2 (ja) 2008-08-27 2016-06-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤
JP5564049B2 (ja) * 2008-09-29 2014-07-30 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ１４７抗体、方法及び使用
EP2379710A1 (en) 2008-12-19 2011-10-26 Schering Corporation Feed supplement for mammalian cell culture and methods of use
WO2010127181A1 (en) * 2009-04-29 2010-11-04 Trellis Bioscience, Inc. Improved antibodies immunoreactive with heregulin-coupled her3
WO2011011797A2 (en) * 2009-07-24 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Cytokine compositions and methods of use thereof
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
SG177025A1 (en) 2010-06-21 2012-01-30 Agency Science Tech & Res Hepatitis b virus specific antibody and uses thereof
DK3789038T3 (da) * 2010-05-14 2022-10-17 Univ Leland Stanford Junior Humaniserede og kimære monoklonale antistoffer mod cd47
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
CA2805653A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
JP6126532B2 (ja) * 2010-11-04 2017-05-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−２３抗体
WO2012112528A1 (en) * 2011-02-18 2012-08-23 Merck Sharp & Dohme Corp. Use of mdl-1 antagonists to treat spondylarthropathy
EP2583979B1 (en) 2011-10-19 2015-12-16 Effimune Methods to prepare antibodies directed against p19 subunit of human IL-23
PT2812443T (pt) 2012-02-06 2019-09-05 Inhibrx Inc Anticorpos cd47 e métodos de utilização dos mesmos
MX368653B (es) 2012-05-03 2019-10-10 Boehringer Ingelheim Int Anticuerpos anti-il-23p19.
CN104884473B (zh) 2012-05-22 2019-12-03 百时美施贵宝公司 Il-17a/f il-23双特异性抗体及其应用
US9803010B2 (en) 2012-06-27 2017-10-31 Merck Sharp & Dohme Corp. Crystalline anti-human IL-23p19 antibodies
EP2888283B1 (en) 2012-08-24 2018-09-19 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
JOP20140049B1 (ar) * 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
NZ712294A (en) 2013-03-15 2020-04-24 Amgen Inc Methods for treating crohn’s disease using an anti-il23 antibody
AU2014238148A1 (en) 2013-03-15 2015-10-08 Amgen Inc. Methods for treating psoriasis using an anti-IL-23 antibody
WO2015031815A2 (en) 2013-08-30 2015-03-05 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
TWI711629B (zh) 2014-09-03 2020-12-01 德商包林格因蓋爾漢國際股份有限公司 靶向IL-23A與TNF-α之化合物及其用途
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
IL307578A (en) * 2015-02-04 2023-12-01 Boehringer Ingelheim Int Methods for treating inflammatory diseases
MX2017013156A (es) 2015-04-14 2018-02-21 Boehringer Ingelheim Int Metodos para tratar enfermedades.
AU2016271857B2 (en) * 2015-06-03 2020-05-28 Affiris Ag IL-23-P19 vaccines
BR112018005175A2 (pt) 2015-09-17 2018-10-16 Amgen Inc predição de resposta clínica a antagonistas de il23 usando biomarcadores de via de il23
WO2017049149A1 (en) 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
TWI733695B (zh) 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
MA43186B1 (fr) * 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
MX2018007589A (es) 2015-12-22 2018-11-09 Amgen Inc Ccl20 como indicador de respuesta clinica a antagonistas de il23.
AU2017250583A1 (en) 2016-04-15 2018-08-16 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
EP3848390A1 (en) 2016-10-14 2021-07-14 Boehringer Ingelheim International GmbH Methods of treating diseases
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3818083A2 (en) * 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US20210277105A1 (en) 2018-07-13 2021-09-09 Astrazeneca Collaboration Ventures, Llc Treating ulcerative colitis with brazikumab
JP2021530697A (ja) * 2018-07-18 2021-11-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
EP3883607A4 (en) 2018-11-20 2022-08-17 Janssen Biotech, Inc. SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
CN114466864A (zh) 2019-06-21 2022-05-10 索瑞索制药公司 多肽
CN114514243A (zh) 2019-06-21 2022-05-17 索瑞索制药公司 多肽
GB201911931D0 (en) * 2019-08-20 2019-10-02 Univ College Cardiff Consultants Ltd Anti-C7 antibody or antibody fragment
JP2023509373A (ja) 2019-12-20 2023-03-08 ノヴァロック バイオセラピューティクス， リミテッド 抗インターロイキン－２３ ｐ１９抗体およびそれの使用方法
WO2021138409A2 (en) * 2019-12-31 2021-07-08 Medstar Health, Inc. Anti-cd160 binding molecules for treating diseases
CN113698480B (zh) * 2021-09-18 2022-07-01 东大生物技术(苏州)有限公司 一组il-23单克隆抗体及其医药用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK0656946T4 (da) 1992-08-21 2010-07-26 Univ Bruxelles Immunoglobuliner uden lette kæder
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
WO1997003715A1 (en) 1995-07-21 1997-02-06 The General Hospital Corporation Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
WO1999054357A1 (fr) 1998-04-14 1999-10-28 Chugai Research Institute For Molecular Medicine, Inc. Nouvelle proteine du type cytokine
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
AU3873200A (en) 1999-03-11 2000-09-28 Schering Corporation Mammalian cytokines; related reagents and methods
ES2300276T5 (es) 1999-09-09 2017-06-02 Merck Sharp & Dohme Corp. P40 de interleuquina-12 de mamífero e interleuquina B30. Sus combinaciones. Anticuerpos. Usos en composiciones farmacéuticas
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
DK1576011T3 (da) 2002-10-30 2009-11-30 Genentech Inc Inhibering af IL-17 produktion
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
AU2004219625B9 (en) 2003-03-10 2010-12-23 Merck Sharp & Dohme Corp. Uses of IL-23 agonists and antagonists; related reagents
AU2004239288B2 (en) 2003-05-09 2010-01-28 Centocor, Inc. IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
PE20090046A1 (es) 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
WO2005120571A2 (en) 2004-06-07 2005-12-22 Ramot At Tel Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
EP3501537A1 (en) 2005-06-30 2019-06-26 Janssen Biotech, Inc. Anti-il23 antibodies, compositions, methods and uses
WO2007024846A2 (en) * 2005-08-25 2007-03-01 Eli Lilly And Company Anit-il-23 antibiodies
EP2354160A1 (en) 2005-08-31 2011-08-10 Schering Corporation Engineered anti-IL-23-antibodies
PL1971366T3 (pl) 2005-12-29 2015-01-30 Janssen Biotech Inc Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie

Also Published As

Publication number Publication date
PL1931710T3 (pl) 2017-06-30
CA2620802A1 (en) 2007-03-08
CY2019041I1 (el) 2020-05-29
US7807160B2 (en) 2010-10-05
CN101296944A (zh) 2008-10-29
JP2009505677A (ja) 2009-02-12
RS55788B1 (sr) 2017-08-31
EP2354160A1 (en) 2011-08-10
US20070048315A1 (en) 2007-03-01
US20110002942A1 (en) 2011-01-06
WO2007027714A3 (en) 2007-06-21
SG10201402712QA (en) 2014-08-28
EP1931710A2 (en) 2008-06-18
HUE032131T2 (en) 2017-09-28
US20090156788A1 (en) 2009-06-18
SG165322A1 (en) 2010-10-28
PT1931710T (pt) 2017-03-28
CY2019041I2 (el) 2020-05-29
WO2007027714A2 (en) 2007-03-08
JP5350793B2 (ja) 2013-11-27
EP3190125A1 (en) 2017-07-12
ME02705B (me) 2017-10-20
DK1931710T3 (en) 2017-04-03
US8362212B2 (en) 2013-01-29
CY1118760T1 (el) 2017-07-12
EP1931710B1 (en) 2017-01-18
LTPA2019520I1 (lt) 2019-11-11
ES2619845T3 (es) 2017-06-27
LT1931710T (lt) 2017-03-27
JP2011130771A (ja) 2011-07-07
HUS1900050I1 (hu) 2019-11-28

Similar Documents

Publication Publication Date Title
HRP20170444T1 (hr) Projektirana anti-il-23 antitijela
RU2016119152A (ru) Стабильные и растворимые антитела, ингибирующие vegf
HRP20120611T1 (hr) Anti-il-23p19 antitijela proizvedena genetiäśkim inžinjerstvom
JP2020079252A5 (hr)
HRP20171690T1 (hr) Antitijela koja se vežu za humani cgrp receptor
ES2517420T3 (es) Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
NZ610153A (en) Novel anti-dr5 antibody
RU2019118359A (ru) Антитело к cd73 человека
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
RU2012112829A (ru) Анти-gitr-антитела
JP2020500538A5 (hr)
JP2018521638A5 (hr)
RU2016129274A (ru) Канинизированные мышиные антитела к человеческому pd-1
PE20061324A1 (es) Anticuerpos anti-il-6, composiciones, metodos y usos
NZ603972A (en) Anti-fgfr2 antibodies
HRP20191590T1 (hr) Protutijela za bubrežni antigen 1 i njihov fragment koji veže antigen
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
CL2013003140A1 (es) Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene.
JP2012532851A5 (hr)
RU2012103212A (ru) Tlr3 связывающие агенты
NZ584726A (en) Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
RU2014145536A (ru) Антитело против adamts-5, его производные и их применение
JP2023093753A5 (hr)
ZA202211246B (en) Bispecific antibody